2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-162523
    hMAO-B-IN-8 98%
    hMAO-B-IN-8 (Compound 23) is a hMAO-B, eeAChE, COX-2 and 5-LOX inhibitor, with IC50 values of 0.037 μM, 0.071 μM, 14.3 μM and 0.59 μM, respectively. hMAO-B-IN-8 can be used for the research of Alzheimer's disease.
    hMAO-B-IN-8
  • HY-162539
    T2-BDP589 98%
    T2-BDP589 is a RIPK1 fluorescent probe, and can be used for the NanoBRET assay.
    T2-BDP589
  • HY-162552
    KOR/DOR agonist 1 98%
    KOR/DOR agonist 2 is a KOR and DOR opioid receptors agonist with Ki values of 0.14 nM, and 0.93 nM, respectively. KOR/DOR agonist 2 shows significant antinociceptive effects. KOR/DOR agonist 2 penetrates the blood-brain barrier.
    KOR/DOR agonist 1
  • HY-162573
    Monoamine Oxidase B inhibitor 5 2969160-15-2 98%
    Monoamine Oxidase B inhibitor 5 (Compound 16d) is a selective and reversible inhibitor for monoamine oxidase B (hMAO-B) with an IC50 of 67.3 nM and a Ki of 82.5 nM. Monoamine Oxidase B inhibitor 5 exhibits good pharmacokinetic characters and weak toxicity in rats model. Monoamine Oxidase B inhibitor 5 alleviates MPTP-induced (HY-15608) motor impairment in Parkinson’s mouse model. Monoamine Oxidase B inhibitor 5 is blood-brain barrier (BBB) penetrate.
    Monoamine Oxidase B inhibitor 5
  • HY-162585
    5-HT1AR agonist 1 98%
    5-HT1AR agonist 1 (Compound A3) emerges as a relatively balanced multi-target activity profile, including 5-HT1AR agonist with an EC50 value of 34 nM, SERT reuptake ihibitor (IC50 =12 nM), NET reuptake inhibitor (IC50 =78 nM) and DAT reuptake inhibitor (IC50 =135 nM). 5-HT1AR agonist 1 performs significant antidepressant effects and exhibits excellent bioavailability and low clearance in mice, which is promising for research in the field of antidepressant drugs.
    5-HT1AR agonist 1
  • HY-162591
    MR33317 98%
    MR33317 is an inhibitor of acetylcholinesterase with an IC50 value of 41nM. MR33317 is also an agonist at brain 5-HT4 receptors.
    MR33317
  • HY-162596
    NRL-1049 1973494-16-4 98%
    NRL-1049 (BA-1049) is a ROCK2 selective inhibitor (IC50: 0.59 µM and 26 µM for ROCK2 and ROCK1 respectively). NRL-1049 reduces Lysophosphatidic acid induced ROCK activation in endothelial cells. NRL-1049 reduces lesion volume and hemorrhagic transformation in a mouse model of cavernous angiomas. NRL-1049 also preserves the BBB and suppresses seizures after brain injury, and inhibits hemorrhagic transformation after ischemic stroke in mice.
    NRL-1049
  • HY-162606
    MAO-A/B-IN-3 315210-31-2 98%
    MAO-A/B-IN-3 (Compound 12) stands out as a key dual MAO-AChE inhibitor, displaying excellent multi-target efficacy against MAO-A, MAO-B, and AChE with IC50 values of 67 nM, 29 nM, and 1370 nM respectively. MAO-A/B-IN-3 is adept at altering the A site (hydrophobic ring) and C site (semicarbazone chain) within ketone amine-based MTDLs to bolster the inhibitory potential against MAO-A/B while notably diminishing activity against AChE. MAO-A/B-IN-3 is poised for research applications in the field of neurodegenerative diseases.
    MAO-A/B-IN-3
  • HY-162609
    ST-2560 98%
    ST-2560 is a selective inhibitor of the NaV1.7 sodium channel with IC50 value of 39 nM. ST-2560 can be used to study pain behavior and cardiovascular models.
    ST-2560
  • HY-162613
    ASM-IN-2 2305789-66-4 98%
    ASM-IN-2 (Compound 46) is a potent ASM inhibitor with an IC50 value of 0.87 μM, displaying good drug-like properties. ASM-IN-2 involves in multiple antidepressant mechanisms of actionin, which are associated with a decline of ceramide. It demostrates remarkable antidepressant effects in the CUMS-induced mouse, which is promising for research in the field of antidepressant drugs.
    ASM-IN-2
  • HY-162636
    5HT6-ligand-2 98%
    5HT6-ligand-2 (compound 15) is a potent 5-HT6 inhibitor with Ki values of 3.4, 15 nM for 5-HT6, SERT, respectively. 5HT6-ligand-2 shows neuroprotection. 5HT6-ligand-2 has the potential for the research of dementia.
    5HT6-ligand-2
  • HY-162638
    GSK-3β inhibitor 18 98%
    GSK-3β inhibitor 18 (compound 2) is a potent inhibitor of GSK-3β, with the IC50 of 0.0021 μM.
    GSK-3β inhibitor 18
  • HY-162639
    α-Glucosidase-IN-68 1624628-01-8 98%
    α-Glucosidase-IN-68 (Compound 2) is an inhibitor for α-Glucosidase, AChE, and BChE, with IC50 of 0.251, 0.774 and 0.793 μM, respectively. α-Glucosidase-IN-68 exhibits antioxidant efficacy, with IC50 of 0.69 μM and 0.02 μM, in DPPH and ABTS experiments. α-Glucosidase-IN-68 exhibits antidiabetic effect in Streptozotocin (HY-13753)-induced diabetic rat models.
    α-Glucosidase-IN-68
  • HY-162652
    HSR-IN-1 98%
    HSR-IN-1 (Compound 28) is an effective hSR (human serine racemase) inhibitor. In the presence of the cofactor Pyridoxal 5'-phosphate monohydrate (HY-W011727A), HSR-IN-1 has a Kd value of 5.4 μM and an IC50 of 18.3 μM for hSR, while the IC50 of HSR-IN-1 alone is 4.7 μM. HSR-IN-1 can be used for research on central nervous system diseases.
    HSR-IN-1
  • HY-162660
    BI-9508 98%
    BI-9508 is a selective and cross the blood-brain barrier GPR88 agonist. BI-9508 has the potential for the research of neurological disorders.
    BI-9508
  • HY-162662
    VU6008677 2170550-99-7 98%
    VU6008677 is a positive allosteric modulator (PAM) for M4, with EC50 of 120 nM for hM4. VU6008677 inhibits cytochrome P450, exhibits good pharmacokinetic characteristics in rats.
    VU6008677
  • HY-162669
    Mu opioid receptor antagonist 8 3040171-60-3 98%
    Mu opioid receptor antagonist 8 (368) is a μ-opioid receptor antagonist. Mu opioid receptor antagonist 8 (368) significantly inhibits met-enkephalin-induced µOR activation of Gi.
    Mu opioid receptor antagonist 8
  • HY-162671
    BuChE-IN-12 1363947-94-7 98%
    BuChE-IN-12 is a selective BuChE inhibitor (IC50=0.52 µM) that acts via affecting CAS and PAS sites and has potential effects against oxidative stress. BuChE-IN-12 can be used in the study of Alzheimer's disease.
    BuChE-IN-12
  • HY-162678
    HDAC-IN-75 98%
    HDAC-IN-75 (5d) is a HDAC inhibitor, with IC50 values of 6.32 nM and 1352 nM for HDAC6 and HDAC1, respectively. HDAC-IN-75 (5d) promotes vision rescue in the atp6v0e1–/– zebrafish model of photoreceptor dysfunction.
    HDAC-IN-75
  • HY-162681
    eeAChE-IN-3 98%
    eeAChE-IN-3 (compound YS3g) is an orally active, potent EeAChE and IL-6 inhibitor with IC50s of 0.54 μM, 0.49 μM, 8.54 μM and 0.57 μM for EeAChE, RatAChE, RatBuChE and IL-6, respectively. eeAChE-IN-3 improves STZ (HY-13753) (Streptozotocin; HY-13753)-induced learning and memory impairment in mice. eeAChE-IN-3 has the potential for Alzheimer's disease (AD) research.
    eeAChE-IN-3
Cat. No. Product Name / Synonyms Application Reactivity